DeepHealth Saige-DX mammography is a cancer detection tool that uses AI to help radiologists to detect the presence or absence of breast cancer, while Quantib Prostate 2.0 MRI is an AI-based software solution that advances the MRI prostate reporting workflow
RadNet receives FDA clearances for its DeepHealth Saige-DX mammography and Quantib Prostate 2.0 MRI AI algorithms. (Credit: Tung Nguyen from Pixabay)
US-based diagnostic imaging services provider RadNet has secured FDA approvals for its DeepHealth Saige-DX mammography and Quantib Prostate 2.0 MRI artificial intelligence (AI) algorithms.
DeepHealth and Quantib operate as AI subsidiaries of RadNet.
According to the firm, Saige-Dx is a cancer detection tool that uses AI to help radiologists to detect the presence or absence of breast cancer.
The tool is said to be a more advanced successor to DeepHealth’s FDA-approved Saige-Q worklist triage software.
Its AI algorithm detects suspicious lesions in mammograms and gives a level of suspicion to each finding as well as the entire case.
RadNet’s Quantib division received the second AI clearance for the Quantib Prostate tool.
It is an AI-based software solution for MRI prostate reporting that can be accessed from the radiologist’s reading station.
The solution has tools like AI-based segmentation and volumetry, PSA density calculation, precise registration and movement correction, one-click segmentation of lesion candidates, PI-RADS scoring support, and standardised reporting to facilitate easy and comprehensive communication of results.
The FDA’s approval was based on the major upgrade of the solution that includes automatic prostate zone segmentation and automated initiation of localisation of lesions on the PI-RADS sector map.
RadNet president and chief executive officer Dr Howard Berger said: “We are very proud that two of our subsidiaries, DeepHealth and Quantib, have received FDA clearance for their flagship products.
“Artificial intelligence will have a transforming impact on radiology and cancer care, and we are committed to delivering those advances to patients and healthcare providers.
“These recent approvals will help us drive improved patient outcomes while lowering costs.”
Berger added: “The Biden administration, through its Cancer Moonshot programme, is committed to significantly reducing the mortality rates from cancer in the coming decades.
“We believe that these AI tools will play an important role in the early detection and diagnosis of cancer, resulting in improved survival rates and better patient outcomes.”